Study guide

9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

Key Takeaways Explain This Topic AI

Post-burn pruritus affects >80% to 90% of recovering burn patients; if untreated, relentless scratching leads to mechanical shear, autograft avulsion, microbial inoculations, hypertrophic scar worsening, severe sleep disturbance, and major psychiatric morbidity.

Pruritus operates through two distinct neurobiological mechanisms: Early Histaminergic Pruritus (inflammatory phase; mast cell degranulation releasing histamine and substance P acting on C-nerve fibers) and Late Neuropathic Pruritus (remodeling phase; aberrant unmyelinated epidermal nerve sprouting and central spinothalamic sensitization).

Step 1 baseline therapy centers on aggressive skin barrier restoration with fragrance-free emollients (mineral oil, white petrolatum, colloidal oatmeal, ceramide creams applied 3–5 times daily), avoidance of hot water, cool compresses, soft cotton apparel, and wearing soft cotton gloves at night to prevent sleep excoriation.

Step 2 oral antihistamine therapy combines non-sedating second-generation H1 antagonists (cetirizine/fexofenadine) for daytime relief with first-generation sedating H1 antagonists (hydroxyzine/diphenhydramine) at bedtime, frequently augmented by H2 antagonists (famotidine/cimetidine) for synergistic vascular receptor blockade.

Step 3 central neuromodulation with gabapentinoids (gabapentin or pregabalin) is the primary, gold-standard therapy for histamine-refractory neuropathic itch, binding alpha-2-delta calcium channel subunits in the spinal dorsal horn to suppress central transmission.

Last updated: August 2026

9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

Core Knowledge: Post-burn pruritus (itch) is one of the most pervasive, distressing, and intractable long-term sequelae of thermal trauma, afflicting > 80 % to 90 % >80\%\text{ to }90\% > 80% to 90% of burn survivors . Far from a mere superficial nuisance, severe post-burn itch impairs physical rehabilitation, disrupts sleep architecture, causes profound psychological anguish, and provokes uncontrollable scratching that shears fragile neo-epithelium, avulses newly placed autografts, and inoculates pathogenic bacteria into healing wounds.

1. Dual Mechanisms: Histaminergic vs. Neuropathic Pruritus

Effective treatment requires understanding that post-burn pruritus is not a static symptom driven solely by histamine. Instead, it evolves across the wound healing trajectory from an acute histaminergic/inflammatory phase to a chronic neuropathic/central sensitization phase . DUAL PATHOPHYSIOLOGY OF POST-BURN PRURITUS

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ 1. EARLY PHASE: HISTAMINERGIC / INFLAMMATORY PRURITUS │
  • │ (Wound Closure & Proliferative Phase: Days to Weeks) │
  • │ • Massive dermal mast cell accumulation & degranulation │
  • │ • Mediators: Histamine, Substance P, Serotonin (5-HT), Prostaglandins│
  • │ • Activation of unmyelinated polymodal C-fiber pruriceptors │
  • │ • Response: Readily responsive to oral H1/H2 antihistamines │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 2. LATE PHASE: NEUROPATHIC / CENTRAL PRURITUS │
  • │ (Scar Maturation & Remodeling Phase: Months to Years) │
  • │ • Aberrant, disorganized sprouting of regenerating C-nerve fibers │
  • │ • Lowered mechanical/thermal activation thresholds (Hyperknesis) │
  • │ • Loss of inhibitory spinal interneurons (Central Sensitization) │
  • │ • Painless stimuli (clothing friction) felt as severe itch (Alloknesis)│
  • │ • Response: REFRACTORY to antihistamines alone; REQUIRES GABAPENTIN │
  • └────────────────────────────────────────────────────────────────────────┘

Comparing the Two Clinical Pruritus Paradigms:

Clinical Characteristic Histaminergic / Inflammatory Itch Neuropathic / Non-Histaminergic Itch

Dominant Timeframe Acute healing & early re-epithelialization (0 to 3 months) Hypertrophic scar remodeling (3 months to years)

Primary Cellular Drivers Degranulating mast cells, eosinophils, inflammatory cytokines Regenerating cutaneous nerve endings, dorsal horn neurons

Key Mediators Histamine, bradykinin, IL-4, IL-13, IL-31, Substance P Calcitonin gene-related peptide (CGRP), Glutamate, NMDA

Sensory Description Burning, prickling, crawling sensation relieved by cool water Deep, intractable, "electric", "internal crawling" itch

Triggering Stimuli Vasodilation, heat, sweating, dry dressing removal Light touch, pressure garments, clothing shear (Alloknesis)

Primary Pharmacotherapy First- and second-generation H1 + H2 Antihistamines Gabapentinoids (Gabapentin / Pregabalin)

2. The Stepwise Multimodal Management Ladder (ABA Practice Guidelines)

Because no single agent eradicates post-burn itch, the American Burn Association (ABA) endorses a stepwise multimodal ladder . Therapies are combined synergistically to target peripheral mast cells, cutaneous nerve endings, and central spinal pathways. STEPWISE MULTIMODAL PRURITUS LADDER

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ STEP 4: Specialized Systemic & Topical Refractory Adjuncts │
  • │ • Topical Doxepin 5%, Capsaicin 0.025%, Topical Lidocaine 4–5% │
  • │ • Systemic Ondansetron (5-HT3), Naltrexone (μ-opioid), SSRIs/Sertraline│
  • │ • Fractional CO2 / Pulsed Dye Laser, TENS neuromodulation │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ STEP 3: Central Neuropathic Modulators (First-Line for Chronic Itch) │
  • │ • Gabapentin (Neurontin): 300 mg TID titrated up to 1800–2400 mg/day │
  • │ • Pregabalin (Lyrica): 75–150 mg PO BID (alternative to gabapentin) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ STEP 2: Combination Oral Antihistamines │
  • │ • Daytime H1: Cetirizine (10–20 mg/day) or Fexofenadine (180 mg/day) │
  • │ • Nighttime H1: Hydroxyzine (25–50 mg qHS) or Diphenhydramine (50 mg) │
  • │ • Adjunctive H2: Famotidine (20 mg BID) or Cimetidine (400 mg BID) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ STEP 1: Foundational Skin Barrier Restoration & Non-Pharmacological │
  • │ • Unscented, high-lipid emollients (petrolatum/ceramides) 3–5x daily │
  • │ • Tepid bathing, mild soap-free cleansers, cool compresses │
  • │ • Loose soft cotton clothing, short fingernails, cotton sleep gloves │
  • └────────────────────────────────────────────────────────────────────────┘
  • 3. Step 1: Foundational Barrier Hydration & Non-Pharmacological Care

Burned skin, newly healed graft sites, and donor areas lack functional sebaceous and eccrine glands, resulting in profound xerosis (dryness) and a defective stratum corneum lipid barrier. Severe xerosis drastically lowers cutaneous itch thresholds.

Essential Nursing Interventions:

Aggressive Emollient Therapy:

Apply thick, fragrance-free, high-lipid moisturizers (e.g., white petrolatum, mineral oil-based ointments, ceramide creams, or colloidal oatmeal formulations) 3 to 5 times daily .

Reapply immediately after bathing within 3 minutes ("soak and seal" method) to trap water within the stratum corneum.

Precaution: Avoid thick petrolatum directly underneath silicone sheeting or custom pressure garments if it causes maceration or garment slippage.

Bathing & Temperature Modification:

Bathe strictly in lukewarm or tepid water (never hot water). High water temperatures trigger cutaneous vasodilation and massive thermal mast cell degranulation, producing severe itch flares.

Use mild, synthetic detergent (syndet) soap-free cleansers with neutral pH (5.5).

Apply clean, cool, moist compresses ( 15 ∘ C 15^{\circ}\text{C} 1 5 ∘ C to 20 ∘ C 20^{\circ}\text{C} 2 0 ∘ C ) to acutely itching grafted zones to stimulate cold-sensitive A-delta fibers, which centrally inhibit C-fiber itch transmission in the dorsal horn.

Mechanical Trauma Protection:

Keep the patient's fingernails trimmed short and filed smooth .

Provide soft 100% cotton gloves for patients to wear during sleep to prevent unconscious nighttime excoriation.

Educate patients to apply gentle manual palm pressure, tap, or stroke intact skin instead of scratching with sharp fingernails.

Dress in loose-fitting, soft, 100% cotton garments; avoid scratchy synthetic fibers or wool.

4. Step 2: Combination Oral Antihistamine Protocols

Antihistamines are foundational during the early histaminergic phase. Monotherapy with a single H1 blocker is frequently inadequate because dermal microvasculature contains both H1 and H2 receptors . SYNERGISTIC DUAL HISTAMINE BLOCKADE

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Mast Cell Degranulation Releases Histamine into Extracellular Space │
  • │ │ │
  • │ ┌──────────────────┴──────────────────┐ │
  • │ ▼ ▼ │
  • │ H1 RECEPTORS ON C-FIBERS H2 RECEPTORS ON DERMAL │
  • │ & DERMAL ENDOTHELIUM VASCULAR SMOOTH MUSCLE │
  • │ • Pruritus signaling transmission • Arteriolar vasodilation │
  • │ • Capillary permeability / edema • Enhanced mediator washout │
  • │ │ │ │
  • │ ▼ ▼ │
  • │ BLOCKED BY: Cetirizine / BLOCKED BY: Famotidine / │
  • │ Hydroxyzine / Fexofenadine Cimetidine │
  • └────────────────────────────────────────────────────────────────────────┘

Clinical Antihistamine Regimens:

Second-Generation H1 Antagonists (Daytime): Cetirizine (10 to 20 mg PO daily) or Fexofenadine (180 mg PO daily) . These agents have high H1 receptor selectivity and minimal blood-brain barrier penetration, providing daytime relief without causing debilitating daytime sedation.

First-Generation H1 Antagonists (Nighttime): Hydroxyzine (25 to 50 mg PO at bedtime) or Diphenhydramine (25 to 50 mg PO qHS) . Their central sedating and anticholinergic properties help suppress nocturnal itch and facilitate sleep.

H2 Receptor Antagonists (Adjunctive Synergists): Famotidine (20 mg PO BID) or Cimetidine (400 mg PO BID) . Adding an H2 blocker suppresses H2-mediated cutaneous vasodilation, providing synergistic relief in refractory cases.

5. Step 3: Central Neuropathic Modulators (Gabapentinoids)

When pruritus persists beyond the acute inflammatory phase or proves refractory to antihistamines, it is driven by neuropathic central sensitization. Gabapentinoids are the undisputed gold standard for neuropathic post-burn pruritus .

Mechanism of Action:

Gabapentin and pregabalin bind with high affinity to the α 2 δ \alpha_2\delta α 2 ​ δ (alpha-2-delta) auxiliary subunit of voltage-gated calcium channels in the dorsal horn of the spinal cord. This blocks calcium influx into presynaptic sensory terminals, suppressing the exocytosis of excitatory neurotransmitters (glutamate, substance P, and CGRP) and blunting the central transmission of itch signals to the thalamus. GABAPENTIN DOSING & TITRATION PROTOCOL

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Initial Dose: 100 to 300 mg PO at bedtime (titrated to minimize ataxia)│
  • │ │ │
  • │ ▼ │
  • │ Progressive Escalation: 300 mg PO TID (900 mg/day) over 3–5 days │
  • │ │ │
  • │ ▼ │
  • │ Therapeutic Target: 300 to 600 mg PO TID (900 to 1800 mg/day) │
  • │ (Maximum Burn Dosing: up to 2400–3600 mg/day divided TID) │
  • │ │ │
  • │ ▼ │
  • │ MANDATORY CLINICAL ADJUSTMENTS: │
  • │ • Renal Impairment: Reduce dose proportionally based on Creatinine Cl │
  • │ • Adverse Effects: Monitor for sedation, dizziness, peripheral edema │
  • │ • Discontinuation: Taper slowly over 1–2 weeks to prevent withdrawal │
  • └────────────────────────────────────────────────────────────────────────┘

Pregabalin (Lyrica): Provides faster linear absorption and higher bioavailability; dosed at 75 to 150 mg PO BID (up to 300 mg BID).

6. Step 4: Specialized Topical, Systemic, and Laser Adjuncts

For severe, chronic, or refractory pruritus resisting Steps 1 through 3, specialized multimodal options are deployed:

Modality Mechanism of Action Clinical Application & Safety Precautions

Topical Doxepin 5% Cream Potent tricyclic blocker of both H 1 H_1 H 1 ​ and H 2 H_2 H 2 ​ receptors (50x more potent than diphenhydramine) Apply sparingly to small, closed grafted areas QID. Precaution: Significant transdermal absorption can cause severe drowsiness, dry mouth, and anticholinergic toxicity; avoid on >10% TBSA open wounds.

Topical Capsaicin (0.025%–0.075%) Depletes Substance P from peripheral unmyelinated C-fiber nociceptors Applied TID–QID to healed scars. Causes intense initial burning/stinging for 3–5 days before desensitization occurs; patient must be counseled not to discontinue prematurely.

Topical Lidocaine (4%–5%) Blocks voltage-gated sodium channels, preventing nerve action potential generation Useful for localized "itch spikes" over hyperinnervated scar bands. Limit total surface application to prevent systemic toxicity.

Ondansetron (Zofran) Central and peripheral 5 -HT 3 5\text{-HT}_3 5 -HT 3 ​ serotonin receptor antagonist 4 to 8 mg PO/IV TID. Blocks serotonergic itch pathways; highly effective for opioid-induced and cholestatic/neuropathic burn itch.

Naltrexone Central μ \mu μ -opioid receptor antagonist 25 to 50 mg PO daily. Reverses endogenous and exogenous opioid-mediated central pruritus (mu-receptor activation in dorsal horn).

Pulsed Dye Laser (PDL) / Fractional C O 2 CO_2 C O 2 ​ Photothermolysis of scar microvasculature; collagen matrix remodeling Dramatically reduces chronic pruritus in thick hypertrophic scars by ablating abnormal capillary loops and reducing cytokine expression.

TENS (Transcutaneous Electrical Stimulation) Activates large-diameter A β A\beta A β fibers, closing the spinal "gate" to C-fiber itch input Applied proximally to healed scar margins for 20–30 minutes BID for localized non-pharmacological relief.